The Wolverine stack is the most widely discussed peptide combination in the recovery and biohacking community, named for the Marvel character's regenerative abilities. It pairs BPC-157 and TB-500 — two peptides that promote tissue repair through fundamentally different biological pathways — with the goal of accelerating healing beyond what either peptide achieves alone.
The rationale is mechanistic complementarity: BPC-157 activates the FAK-paxillin signaling pathway and promotes angiogenesis (new blood vessel formation), while TB-500 upregulates actin to enhance cell migration to injury sites. Together, they address two critical steps in tissue repair — vascularization and cellular infiltration — through independent mechanisms.
Important: Neither BPC-157 nor TB-500 is FDA-approved for any human use. Both are research compounds currently under FDA reclassification review. No human clinical trials have studied the Wolverine stack combination. This guide is for educational purposes only and does not constitute medical advice. All injury treatment should involve a qualified healthcare provider.
Together, they address two critical steps in tissue repair — vascularization and cellular infiltration — through independent mechanisms.
The peptides
Why these work together
The Wolverine stack's theoretical advantage lies in targeting two distinct bottlenecks in the healing cascade. Tissue repair requires both adequate blood supply to deliver nutrients and immune cells (addressed by BPC-157's angiogenic effects) and efficient migration of repair cells to the injury site (addressed by TB-500's actin upregulation).
BPC-157 works primarily through the FAK-paxillin pathway, which governs cell adhesion and tissue remodeling, and through nitric oxide modulation, which regulates blood vessel formation. TB-500 works through a separate pathway: it sequesters G-actin monomers to promote the formation of F-actin filaments, which are the structural backbone of cell movement.
Because these mechanisms are biologically independent — BPC-157 does not upregulate actin, and TB-500 does not activate the FAK-paxillin pathway — the combination is hypothesized to provide additive or synergistic healing effects. However, this hypothesis remains untested in controlled studies. All evidence for the combination comes from mechanistic reasoning and anecdotal reports, not from trials studying the pair together.
Suggested protocol
Full doses of both peptides to establish therapeutic levels. BPC-157 injected near the injury site for localized effect; TB-500 injected at any subcutaneous site (systemic action).
BPC-157 continues at full dose while TB-500 reduces to maintenance frequency. Most users report significant healing progress by this phase.
For injuries requiring continued healing support. BPC-157 at reduced dose, TB-500 discontinued. Follow with a 2–4 week break before any repeat cycle.
Safety considerations
Generally well-tolerated in preclinical studies. Occasional nausea, dizziness, injection site irritation. Theoretical concern about angiogenesis supporting tumor vascularization.
Reported: lethargy, head rush, injection site redness. No human clinical trial data. Banned by WADA.
The combination of all three peptides has never been studied in clinical trials. Additive side effects, drug interactions, and long-term safety are unknown. Not appropriate for individuals with active or prior pancreatitis, MEN 2 syndrome, active cancer, or during pregnancy/breastfeeding. Physician supervision is essential.
Frequently asked questions
The Wolverine stack is a combination of BPC-157 and TB-500 — two peptides with complementary tissue repair mechanisms. BPC-157 promotes angiogenesis and activates the FAK-paxillin healing pathway, while TB-500 upregulates actin to enhance cell migration. Named after the Marvel character's regenerative abilities, it is the most commonly discussed recovery peptide combination in the biohacking community.
Anecdotal reports from the biohacking community typically describe initial improvement in 1-2 weeks, with significant healing progress over 4-8 weeks depending on injury type and severity. Preclinical BPC-157 studies show accelerated healing within days to weeks in animal models. Individual responses vary significantly based on injury type, overall health, and concurrent rehabilitation.
BPC-157 and TB-500 can be administered on the same day but are typically injected separately rather than mixed in the same syringe, as stability data for the combined solution is not available. Some protocols separate the injections by several hours. TB-500 acts systemically regardless of injection site, while BPC-157 is often injected near the injury for localized effect.
Both BPC-157 and TB-500 are currently under FDA reclassification review. They were previously available as research chemicals from US vendors; most ceased sales in 2025-2026. They are banned by WADA and most sports organizations. Legal status varies by jurisdiction and should be verified before acquisition.
The Wolverine stack is most commonly discussed in the context of tendon injuries (Achilles, rotator cuff, tennis elbow), ligament sprains, muscle tears, and chronic joint pain. BPC-157 has additional preclinical evidence for GI tract healing. The stack is also used in general recovery from surgery. All evidence is preclinical or anecdotal — no human trials have studied this combination for any specific injury.
Reported side effects are generally mild: nausea, headache, dizziness, lethargy, and injection site irritation. Both peptides are considered well-tolerated based on preclinical data and community reports. However, long-term safety data from human trials does not exist. Theoretical concerns include BPC-157's angiogenic properties in the context of existing tumors. Anyone with a cancer history should consult an oncologist before use.